TP53 and B-cell chronic lymphocytic leukemia: These findings corroborate those observed for patients with R/R TP53 aberrant CLL in MURANO at 5-year follow-up; both TP53 disruption and/or genomic complexity were associated with lower EOT uMRD rates, inferior PFS, and OS following 24-month VenR [126].